Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
A startup called Genome Liberty is developing a consumer genetics test to gauge an individual’s ability to metabolize prescription drugs.
It’s hard to get straightforward health guidance from personal genome tests, which are banned in some places. But one way to make them more meaningful is to let more people buy them.
The FDA is unlikely to rule out personal genetics tests, but it may require that physicians get more involved.
Studies show that the genetic risk of disease varies between different ethnic groups, and data on some groups is lacking.
The mutations that trigger cancer progression suggest that a shift is needed in drug development.
Craig Venter and colleagues compare consumer genetic tests and suggest ways to make them more useful.